Perjeta’s Data, Not Regimen, Get FDA Reviewer Support Ahead Of ODAC

Roche/Genentech’s HER2-targeted therapy pertuzumab has sufficient evidence for accelerated approval in neoadjuvant breast cancer, agency briefing documents conclude, but reviewers question use of an anthracycline-containing chemotherapy regimen.